- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04793529
Is Involucrin Has a Role in Verruca Vulgaris? A Clinical and Immunohistochemical Study
July 25, 2023 updated by: Essam Mohamed El-sayed Akl, Benha University
Vitamin D3 plays important role in keratinocyte differentiation and had been used recently in verruca vulgaris.
Aim of the work: To assess the expression of involucrin in verrucae vulgaris before and after injection of vitamin D3.
Subjects and Methods: This study included 60 patients with verrucae vulgaris subjected to intralesional injection of vitamin D3 at three weeks interval for a maximum of five sessions.
Immunohistochemical assessment of involucrin was done before and after injection and compared to skin biopsies from 30 healthy individuals
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Banhā, Egypt
- Essam Mohamed El-sayed Akl
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion criteria:
Patients with multiple verruca vulgaris Patients with with verrucae vulgaris with size more than 3 cm
Exclusion Criteria:
Patients with a past history of allergic response to vitamin D. Pregnant or lactating females. Hepatic patients. Renal patients. Patients with bleeding tendency.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cholecalciferol injection
|
Cholecalciferol injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Resolution of verrucae
Time Frame: 3 months
|
Decrease of verrucae size Decrease of verrucae number
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Involucrin expression
Time Frame: 3 months
|
Change of expression pattern of involucrin by immunohistochemical study Change of expression grade of involucrin by immunohistochemical study
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2019
Primary Completion (Actual)
October 1, 2019
Study Completion (Actual)
October 1, 2019
Study Registration Dates
First Submitted
March 4, 2021
First Submitted That Met QC Criteria
March 9, 2021
First Posted (Actual)
March 11, 2021
Study Record Updates
Last Update Posted (Actual)
July 27, 2023
Last Update Submitted That Met QC Criteria
July 25, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Virus Diseases
- Infections
- DNA Virus Infections
- Skin Diseases, Infectious
- Papillomavirus Infections
- Skin Diseases, Viral
- Tumor Virus Infections
- Warts
- Physiological Effects of Drugs
- Micronutrients
- Vitamins
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Vitamin D
- Cholecalciferol
Other Study ID Numbers
- RC-2-3-2021
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Verruca Vulgaris
-
Minneapolis Veterans Affairs Medical CenterMinnesota Medical FoundationCompletedPlantar Wart | Wart | Common Wart | Verruca Vulgaris | Verruca PlantarisUnited States
-
Alexandria UniversityRecruiting
-
Verrica Pharmaceuticals Inc.BioClinica, Inc.; Paidion Research, Inc.; Instat Consulting, Inc.; ALMAC Clinical...CompletedSkin Diseases | Virus Diseases | DNA Virus Infections | Skin Diseases, Infectious | Warts | Papillomavirus Infections | Skin Diseases, Viral | Tumor Virus Infections | Common Wart | Verruca Vulgaris | Warts Hand | VerrucaUnited States
-
Veloce BioPharma LLCActive, not recruiting
-
Saint Joseph Mercy Health SystemTerminatedVerruca VulgarisUnited States
-
Nielsen BioSciences, Inc.Completed
-
North Idaho DermatologyCompletedVerruca VulgarisUnited States
-
Veloce BioPharma LLCCompleted
-
National Taiwan University HospitalUnknown
-
Neal D. Bhatia, MDLEO PharmaCompletedVerruca Vulgaris | Common WartsUnited States
Clinical Trials on Cholecalciferol
-
Medical University of South CarolinaTerminatedVitamin D Deficiency | Nutritional DeficiencyUnited States
-
Centre of Postgraduate Medical EducationUnknownInfant, Premature, DiseasesPoland
-
Johns Hopkins UniversityNational Institute on Aging (NIA)TerminatedVitamin D Deficiency | FallsUnited States
-
Rashid Centre for Diabetes and ResearchCompletedObesity | Type 2 Diabetes Mellitus | Hypovitaminosis DUnited Arab Emirates
-
University of PittsburghNational Heart, Lung, and Blood Institute (NHLBI)CompletedCystic Fibrosis | Allergic Bronchopulmonary AspergillosisUnited States
-
University Hospitals Cleveland Medical CenterUniversity of Colorado, DenverCompletedInflammationUnited States
-
University Hospital, AngersMylan LaboratoriesCompleted
-
Medical University of South CarolinaEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompleted
-
Assistance Publique - Hôpitaux de ParisLaboratoire CrinexCompletedRenal Transplant Candidate for Right KidneyFrance